Promising early results for rare psoriasis drug
NCT ID NCT03619902
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a drug called imsidolimab in 8 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition. The drug is an antibody that targets inflammation. Researchers measured how well it worked using skin scores and other health markers. The goal was to see if the drug could safely control symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Imsidolimab (a lab-made antibody that targets inflammation)
What this could lead to
If successful, this could point toward a new treatment option to control flare-ups in people with generalized pustular psoriasis.
What could go wrong
This is a very small early-phase trial with only 8 participants, so results may not apply to everyone. The drug may not work in larger studies or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 100
Ann Arbor, Michigan, 48109, United States
-
Site 101
Indianapolis, Indiana, 46250, United States
-
Site 102
Encino, California, 91436, United States
-
Site 104
Miami, Florida, 33316, United States
-
Site 105
Largo, Florida, 33771, United States
-
Site 201
London, United Kingdom
-
Site 202
Salford, United Kingdom
-
Site 203
Newcastle upon Tyne, United Kingdom
-
Site 301
Rzeszów, 35-055, Poland
-
Site 302
Lodz, Poland
-
Site 303
Lodz, 90-436, Poland
-
Site 304
Olsztyn, 10-229, Poland
-
Site 501
Seoul, 03722, South Korea